TY - JOUR
T1 - In Vitro Anti-Amebic Activity of Cage Xanthones from Cratoxylum sumatranum Stem Bark against Entamoeba histolytica
AU - Wardana, Fendi Yoga
AU - Sari, Defi Kartika
AU - Adianti, Myrna
AU - Permanasari, Adita Ayu
AU - Tumewu, Lidya
AU - Nozaki, Tomoyoshi
AU - Widyawaruyanti, Aty
AU - Hafid, Achmad Fuad
N1 - Funding Information:
This research was supported by PDUPT research grant (No.615/ UN3.14/LT/2019) from the Indonesian Ministry of Research and Technology, Japan International Cooperation Agency (JICA) (No.518/ UN3/2015).
Publisher Copyright:
© 2020 Phcogj.Com. This is an open-access article distributed under the terms of the Creative Commons Attribution 4.0 International license.
PY - 2020/5
Y1 - 2020/5
N2 - Background: Amoebiasis is caused by Entamoeba histolytica, which is a pathogenic species living on human colon tissues. The development of new drugs for anti-amebic are still very needed for clinical treatment. Objective: This aims to identify the compounds in Cratoxylum sumatranum for their anti-amoeba activity. Materials and Methods: In this study we used bioactivity-guided isolation and structural analysis to identified anti-amebic compounds from dichloromethane extract of Cratoxylum sumatranum stem bark. Their anti-amebic activity was determined by an in vitro cell-based assay against Entamoeba histolytica and an enzymatic assay on NAD kinase. Results: Two known compounds from the cage xanthone groups, namely cochinchinoxanthone (1) and cochinchinone D (2), were isolated. The structures of the cage xanthone compounds were established by extensive spectroscopic data analysis. Compound (1) showed the greatest level of anti-amebic activity both in cell-based and enzymatic assay, yielding IC50 values of 4.57 and 12.17 µg/mL, respectively. In contrast, compound (2) yielded IC50 values of 5.19 and 12.60 µg/mL, respectively. Conclusion: When considering the demonstrated anti-amebic activities, it becomes apparent that these compounds, isolated from Cratoxylum sumatranum stem bark, have the potential to be further developed into effective anti-amebic medicine against Entamoeba histolytica.
AB - Background: Amoebiasis is caused by Entamoeba histolytica, which is a pathogenic species living on human colon tissues. The development of new drugs for anti-amebic are still very needed for clinical treatment. Objective: This aims to identify the compounds in Cratoxylum sumatranum for their anti-amoeba activity. Materials and Methods: In this study we used bioactivity-guided isolation and structural analysis to identified anti-amebic compounds from dichloromethane extract of Cratoxylum sumatranum stem bark. Their anti-amebic activity was determined by an in vitro cell-based assay against Entamoeba histolytica and an enzymatic assay on NAD kinase. Results: Two known compounds from the cage xanthone groups, namely cochinchinoxanthone (1) and cochinchinone D (2), were isolated. The structures of the cage xanthone compounds were established by extensive spectroscopic data analysis. Compound (1) showed the greatest level of anti-amebic activity both in cell-based and enzymatic assay, yielding IC50 values of 4.57 and 12.17 µg/mL, respectively. In contrast, compound (2) yielded IC50 values of 5.19 and 12.60 µg/mL, respectively. Conclusion: When considering the demonstrated anti-amebic activities, it becomes apparent that these compounds, isolated from Cratoxylum sumatranum stem bark, have the potential to be further developed into effective anti-amebic medicine against Entamoeba histolytica.
KW - Amoebiasis
KW - Bioactivity-guided isolation
KW - Cratoxylum sumatranum
KW - Entamoeba histolytica
KW - NAD kinase
UR - http://www.scopus.com/inward/record.url?scp=85084747517&partnerID=8YFLogxK
U2 - 10.5530/pj.2020.12.70
DO - 10.5530/pj.2020.12.70
M3 - Article
AN - SCOPUS:85084747517
SN - 0975-3575
VL - 12
SP - 452
EP - 458
JO - Pharmacognosy Journal
JF - Pharmacognosy Journal
IS - 3
ER -